Larimar Therapeutics Statistics
Total Valuation
LRMR has a market cap or net worth of $120.37 million. The enterprise value is -$57.96 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LRMR has 64.03 million shares outstanding. The number of shares has increased by 39.53% in one year.
| Current Share Class | 64.03M |
| Shares Outstanding | 64.03M |
| Shares Change (YoY) | +39.53% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 1.17% |
| Owned by Institutions (%) | 49.89% |
| Float | 31.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.70 |
| P/TBV Ratio | 0.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.02, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.02 |
| Quick Ratio | 7.58 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -63.58% and return on invested capital (ROIC) is -43.00%.
| Return on Equity (ROE) | -63.58% |
| Return on Assets (ROA) | -38.36% |
| Return on Invested Capital (ROIC) | -43.00% |
| Return on Capital Employed (ROCE) | -51.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.24M |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.99% in the last 52 weeks. The beta is 0.91, so LRMR's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | -72.99% |
| 50-Day Moving Average | 2.68 |
| 200-Day Moving Average | 5.77 |
| Relative Strength Index (RSI) | 37.26 |
| Average Volume (20 Days) | 1,010,139 |
Short Selling Information
The latest short interest is 4.82 million, so 7.52% of the outstanding shares have been sold short.
| Short Interest | 4.82M |
| Short Previous Month | 5.08M |
| Short % of Shares Out | 7.52% |
| Short % of Float | 15.37% |
| Short Ratio (days to cover) | 5.45 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -90.89M |
| Pretax Income | -58.34M |
| Net Income | -80.60M |
| EBITDA | -90.57M |
| EBIT | -90.89M |
| Earnings Per Share (EPS) | -$1.32 |
Full Income StatementBalance Sheet
The company has $183.45 million in cash and $5.12 million in debt, giving a net cash position of $178.34 million or $2.79 per share.
| Cash & Cash Equivalents | 183.45M |
| Total Debt | 5.12M |
| Net Cash | 178.34M |
| Net Cash Per Share | $2.79 |
| Equity (Book Value) | 171.81M |
| Book Value Per Share | 2.69 |
| Working Capital | 170.95M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$70.76 million and capital expenditures -$515,000, giving a free cash flow of -$71.28 million.
| Operating Cash Flow | -70.76M |
| Capital Expenditures | -515,000 |
| Free Cash Flow | -71.28M |
| FCF Per Share | -$1.11 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |